Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

October 31, 2011

Conditions
Kidney Cancer
Interventions
DRUG

Perifosine

"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."

Trial Locations (3)

10504

Investigative Site, Armonk

40202

Investigative Site, Louisville

07962

Investigative Site, Morristown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AEterna Zentaris

INDUSTRY

NCT00498966 - Ph II Study of Perifosine for Patients With Carcinoma of the Kidney | Biotech Hunter | Biotech Hunter